JP Morgan Raises JNJ Price Target to $285.00 Amid Overvaluation Concerns

JP Morgan has maintained its 'Neutral' rating for Johnson & Johnson (JNJ) while increasing its price target from $270.00 to $285.00, reflecting a 5.56% change.

This adjustment comes amidst a backdrop of varying analyst opinions on the stock. JNJ is currently significantly overvalued, with a GF Value™ of $193.81 compared to its current trading price of $270.35, indicating a margin of safety that is not present for potential investors.

The strong overall performance in various financial metrics is reflected in JNJ's GF Score™ of 81/100, which suggests solid fundamentals. However, the current valuation metrics raise concerns about the stock's attractiveness at its present price level.